NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
02/21/2026
Back to search
Official data from USPTO
XBRANE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
03/17/2026
Trademark type
Combined
Nice classes
5, 10, 42
Filing date
11/12/2018
Registration date
03/10/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/21/2026
Last transaction
03/17/2026
Responsible office
United States Patent and Trademark Office
Status code
707
Official register
Principal Register
Drawing code
5
Owner type
09
Owner location
SOLNA, SE
Examiner
GARDNER, DAWNA BERYL
Current location
Historical data usage
Mark description
The mark consists of the stylized light blue and dark blue wording "XBRANE".
Holders and representatives
Holders
Xbrane Biopharma AB
Xbrane Biopharma AB
Representatives
Andy I. Corea Harris Beach Murtha Cullina PLLC
Technical classification
Nice Classes
Class 5Class 10Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and medical preparations all for treating cancerendometriosismyomaeye diseasesage related macular degenerationskin diseasesprecocious pubertyvascular diseasescardiovascular diseases and disordersoncological diseases and disordersimmune diseases and disordersautoimmune diseasesangiogenesis diseases and disordersgenetic conditionsinfectious diseasesocular diseases and disordersinflammatory diseases and disordersrheumatoid arthritispsoriatic arthritisankylosing spondylitispsoriasisCrohn's diseaseulcerative colitisdiabetesdiabetic macular edemadiabetic related retinopathymultiple sclerosisarthritisosteoporosisbone metastasis; generic pharmaceutical preparations and biological pharmaceutical preparations all for treating cancerendometriosismyomaeye diseasesage related macular degenerationskin diseasesprecocious pubertyvascular diseasescardiovascular diseases and disordersoncological diseases and disordersimmune diseases and disordersautoimmune diseasesangiogenesis diseases and disordersgenetic conditions and infectious diseases; generic pharmaceutical preparations and biological pharmaceutical preparations all for treating ocular diseases and disordersinflammatory diseases and disordersrheumatoid arthritispsoriatic arthritisankylosing spondylitispsoriasisCrohn's diseaseulcerative colitisdiabetesdiabetic macular edemadiabetic related retinopathymultiple sclerosisarthritisosteoporosisbone metastasis; chemotherapeutics; hormones for medical purposes; pharmaceutical agents for treating metabolic disorders; amino acids for medical purposes; pharmaceutical agents for treating immunity disorders; pharmaceutical agents for treating physically caused lesions; antiviral preparations; diagnostic kits consisting primarily of monoclonal antibodies for the diagnosistreatment and prevention of cancerendometriosismyomaeye diseasesage related macular degenerationskin diseasesprecocious pubertyvascular diseasescardiovascular diseases and disordersoncological diseases and disordersimmune diseases and disordersautoimmune diseasesangiogenesis diseases and disordersgenetic conditionsinfectious diseases; diagnostic kits consisting primarily of monoclonal antibodies for the diagnosistreatment and prevention of ocular diseases and disordersinflammatory diseases and disordersrheumatoid arthritispsoriatic arthritisankylosing spondylitispsoriasisCrohn's diseaseulcerative colitisdiabetesdiabetic macular edemadiabetic related retinopathymultiple sclerosisarthritisosteoporosis and bone metastasis
Class 10
Surgical apparatus and instruments; injection device for pharmaceuticals; injection syringes; injection needles; medical apparatusautomatic infusion and injection devices for administering drugs to humans
Class 42
Scientific and medical research and development; pharmaceutical research and development services; research and development services in the fields of biological similar pharmaceuticalsgeneric drugsbiotechnologydiagnostics and pharmaceuticals; consultancy services relating to the discovery and evaluation of drugs and chemical compounds having diagnostic properties and therapeutic properties; technical support servicestroubleshooting in the nature of diagnosing problems with medical equipment; diagnostic services in the field of troubleshooting biotechnology and pharmaceutical equipment for scientific research purposes; analyzing biotechnology and pharmaceutical equipment for scientific research purposes; development of new technology for others in the field of biotechnology; medicalpharmaceutical and biotechnological laboratory research services; informationconsultancy and advisory services relating to scientific and medical research and developmentbiotechnological and pharmaceutical research and development and medical equipment research and development
Publications
History of USPTO decisions and trademark events.
36 publications found
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
02/21/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/09/2026
ES71
TEAS SECTION 71 RECEIVED
10/03/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
03/10/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/31/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/11/2020
FIMP
FINAL DISPOSITION PROCESSED
07/11/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/10/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
03/10/2020
GPNX
NOTIFICATION PROCESSED BY IB
01/03/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/24/2019
PUBO
PUBLISHED FOR OPPOSITION
12/24/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/18/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
12/18/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/04/2019
ALIE
ASSIGNED TO LIE
11/19/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/15/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/07/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/07/2019
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
11/07/2019
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
07/09/2019
GNFR
FINAL REFUSAL E-MAILED
07/09/2019
CNFR
FINAL REFUSAL WRITTEN
07/09/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/12/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/12/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/12/2019
RFNT
REFUSAL PROCESSED BY IB
04/06/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/20/2019
RFRR
REFUSAL PROCESSED BY MPU
03/20/2019
MAFR
APPLICATION FILING RECEIPT MAILED
03/09/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/08/2019
CNRT
NON-FINAL ACTION WRITTEN
03/07/2019
DOCK
ASSIGNED TO EXAMINER
03/05/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/05/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/28/2019
Continuous trademark protection
Get notified about every new filing that threatens XBRANE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.